Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Figure out How to Score Huge with Open Record Rewards - 2Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- 3Moon memorial: Artemis 2 astronauts name lunar 'bright spot' after mission commander's late wife
- 4Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- 5How Trump's marijuana executive order could change medical research landscape
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- Truly amazing Palaces: Which Is Your Number one?
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- Becoming the best at Discussion: Individual Procedures
- Novo Nordisk cuts Wegovy price in South Africa for a second time
